Clarity Pharmaceuticals (ASX:CU6) Current Accrued Expense: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
30 GF Score
Price A$2.63
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Current Accrued Expense?

Clarity Pharmaceuticals ASX:CU6 -6.07% 30 Current Accrued Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Clarity Pharmaceuticals's Current Accrued Expense for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Clarity Pharmaceuticals Current Accrued Expense Related Terms

Clarity Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Current Accrued Expense Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Current Accrued Expense
0.00 0.00 0.00 0.00

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CU6
30GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of A$0.00 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Current Accrued Expense of A$0.00 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Current Accrued Expense too high?
Clarity Pharmaceuticals' current Current Accrued Expense is A$0.00 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Current Accrued Expense compare to VRTX and REGN?
Clarity Pharmaceuticals' Current Accrued Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Current Accrued Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Current Accrued Expense of A$0.00 Mil. The current Current Accrued Expense is A$0.00 Mil. Clarity Pharmaceuticals' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Current Accrued Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
30GF Score

Get the complete analysis for ASX:CU6

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.63
Price